Melanoma Vaccines: Comparing Novel Adjuvant Treatments in High-Risk Patients
<b>Background:</b> The emergence of checkpoint inhibitors (CPIs) has significantly improved survival outcomes in later-stage melanoma. However, the efficacy of these treatments remains limited, with around 50% of later-stage melanoma patients experiencing recurrence. As variable response...
Bewaard in:
| Hoofdauteurs: | , , , , , |
|---|---|
| Formaat: | Artikel |
| Taal: | Engels |
| Gepubliceerd in: |
MDPI AG
2025-06-01
|
| Reeks: | Vaccines |
| Onderwerpen: | |
| Online toegang: | https://www.mdpi.com/2076-393X/13/6/656 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|